Caresyntax Inc. develops a technology platform specializing in surgical analytics to enhance safety and efficiency in hospitals and ambulatory surgical centers. The company offers solutions designed to identify and manage risks, automate workflows, and reduce variability in surgical procedures. Its flagship products include qvident, a performance management software that enables surgical teams to create and share surgical content, and PRIME365, an integration platform that consolidates key surgical data from various sources such as video, audio, patient vitals, and procedural timestamps. Caresyntax's offerings support a range of surgical procedures, from minimally invasive to robotic surgeries, and can be deployed as HIPAA-compliant software through on-premise, cloud-based, or hybrid installations. Established in 1991, Caresyntax is headquartered in Boston, Massachusetts.
WHILL is a company that designs and manufactures personal mobility products suitable for both indoor and outdoor use, aiming to enhance transportation experiences for all individuals. Founded in 2013 and based in San Carlos, California, WHILL seeks to redefine the perception of mobility devices like wheelchairs and scooters through innovative technology and thoughtful design. In addition to creating and selling mobility vehicles, WHILL offers mobility-as-a-service, which includes autonomous transportation solutions and on-site fleet rentals. This service enhances accessibility in public spaces such as airports, hospitals, and tourist destinations, allowing users to navigate these environments without a driver's license and promoting a more independent lifestyle for wheelchair users.
Claro is a WSI / virtual slide equipment manufacturer.
INSPEC INC. finds technologies that supports people lives.
Tocagen Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on cancer-selective gene therapy. Founded in 2007, Tocagen develops innovative therapies designed to activate the immune system against cancer. Its primary platform utilizes retroviral replicating vectors (RRVs) to deliver therapeutic genes directly into the DNA of cancer cells. The company’s lead product candidates, Toca 511 and Toca FC, are under investigation in Phase III clinical trials for treating recurrent high-grade glioma, a challenging brain cancer. Additionally, Tocagen is exploring the use of these candidates in a Phase Ib trial for advanced cancers and has collaborations in place to further their development. The company holds a license agreement with ApolloBio for Toca 511 and Toca FC and collaborates with NRG Oncology on clinical trials for newly diagnosed glioblastoma patients.
Immuno-Biological Laboratories specializes in the research, development, manufacturing, and supply of immunological research reagents and customized services. The company focuses on creating materials for diagnostic products and valuable seeds, aiming to secure approval for their use in in-vitro diagnostics and therapeutic applications. A key aspect of their innovation involves utilizing transgenic silkworm cocoons for protein production, which allows for the generation of valuable proteins and antibodies. Additionally, the company conducts research on clinical reagents specifically for cancer research, developing inflammatory cytokines, growth factors, and antibodies to combat various cancers.
ALBERT Inc. is a Tokyo-based company that specializes in providing analytical data solutions in Japan. Founded in 2005, it focuses on various aspects of big data analytics, including marketing research, multivariate statistics, data mining, and analytical text and image analysis. The company also engages in big data processing, solutions development, platform building, and engineering optimization modeling. Through its comprehensive services, ALBERT aims to support clients in leveraging data for informed decision-making and strategic planning.
FRONTEO is driven from a service-oriented culture that continues to aim higher and brighter to develop leading-edge technology and market best services creating immense value for their clients, employees, consumers and shareholders.
Their focus, defined by their name, is to look to the future and innovate around how to even further apply their AI technology to Legal and other business verticals. Within Legal, they’ll be continuing to refine their technology assisted review process, predictive analytics and Business Intelligence. They continue to develop their FRONTEO TRUST Business Intelligence Portal with enhanced reporting for database usage, spend and project management, to provide visibility and actionable reporting to their clients. In other verticals like healthcare, retail and marketing, they’ll be implementing their Artificial Intelligence technology to help make the world a better place, and add value for their clients. They are moving forward to a brighter future!
MedRx is a pharmaceutical company that develops pharmaceutical drugs based on the transdermal absorption system in Japan. It develops medicines based on Ionic Liquid Transdermal System. The company’s products in the pipeline include MRX-4TZT; MRX-5LBT; MRX-10XT; and MRX-5DML. It also offers microneedle patch for delivery of vaccines and/or APIs through the skin. MedRx Co., Ltd. was founded in 2002 and is headquartered in Higashikagawa, Japan.
SymBio Pharmaceuticals Limited is a biopharmaceutical company based in Tokyo, Japan, focused on the research, development, manufacturing, and marketing of pharmaceutical drugs, primarily in the fields of oncology and hematology. The company develops various anti-cancer agents, including Treakisym, which is used to treat non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia, and is currently undergoing Phase III trials for relapsed/refractory diffuse large B-cell lymphoma. Additionally, SymBio is working on several other drug formulations, including SyB L-1701, SyB L-1702, and Rigosertib SyB-C-0501, as well as SyB L-1101 and SyB C-1101 for higher-risk myelodysplastic syndromes. The company also has a candidate, SyB V-1901, aimed at treating infectious diseases. SymBio Pharmaceuticals operates primarily in Japan, South Korea, China, Hong Kong, Taiwan, and Singapore.
CRI Middleware Co Ltd is a provider of audio and video solutions for the gaming industry. It is engaged in the research and development of voice, video and file systems. Further, it also provides sales and support of middleware products. Geographically, the activities are carried out through the region of Japan.
Medinet Co., Ltd. is a contract development and manufacturing organization based in Tokyo, Japan, specializing in regenerative medicine and cell therapy solutions. Founded in 1995, the company offers a comprehensive suite of services designed to support medical institutions, research facilities, and biopharmaceutical companies in the implementation of immuno-cell therapy. Its offerings include technical expertise, specialized facilities, and essential materials, along with professional cell-engineers. Medinet's value chain solutions encompass personnel training, facility design, operational management, logistics, and quality control systems. By providing these resources, Medinet aims to facilitate the broader application of immuno-cell therapy, which has traditionally faced limitations due to the complex requirements and high costs associated with its implementation.
NanoCarrier Co., Ltd. is a Japanese pharmaceutical company that specializes in the research, development, production, and sale of cancer treatment products utilizing micellar nanoparticle technology. Founded in 1996 and headquartered in Kashiwa, Japan, the company has developed a diverse product pipeline aimed at various types of cancer. Key products include NC-6004, a Cisplatin micelle targeting cancers such as pancreatic and lung cancer; VB-111, a non-replicating Adeno 5 vector for treating recurrent glioblastoma and ovarian cancer; and NC-6300, an Epirubicin micelle for soft tissue sarcoma. Additional candidates include NC-4016, a Dach-platinum micelle for solid tumors, and NK105, a Paclitaxel micelle aimed at breast and gastric cancers. NanoCarrier is focused on advancing its innovative technologies to improve treatment options for cancer patients.
Hearts United Group provides VR sickness scoring service.
Shoubunsha Publications is a publishing company engaged in planning, production, publishing, and sale of maps, magazines, and guidebooks, as well as geographical information systems. The company is also engaged in the publication of periodical touring, shopping and driving guides, and electronic mapping for car navigation systems, as well as engaged in the planning, production, and sale of digital database contents and the provision of database-related services. Some of the company’s publications include road atlases of Japan, which are marketed under the name Mapple, prefecture atlases under the name Newest, and sheet maps under the name of Area Map. It also publishes travel guide books under the name Acchi Kocchi, various travel information magazines and digital map database under the name SiMAP. Shoubunsha Publications also offers geographical information system products, CD-ROMs, and other electronic publications. Shobunsha Publications was founded in 1960 and is headquartered in Tokyo, Japan.
Nanodex is an R&D venture company that provides the synthesis and application of folate-modified cyclodextrins as artificial cancer antibodies. It is based in Tokyo, Japan.
CellSeed Inc. is a biotechnology company based in Tokyo, Japan, that specializes in the development of regenerative medicine products, focusing primarily on markets in Japan and Europe. Founded in 2001, the company conducts research, development, manufacturing, and marketing of cell-sheet regenerative medicines. Its product offerings include epithelial cell sheets for corneal and esophageal regeneration, regenerated cardiac patches for heart disease treatment, cell sheets for periodontal tissue regeneration, and regenerated cartilage sheets for osteoarthritis. Additionally, CellSeed provides innovative cell cultureware products designed for cell-sheet engineering and collection, as well as contract development and manufacturing services.
Advanced Media is a Japanese company based in Tokyo that specializes in the development of voice recognition technology through its proprietary AmiVoice platform. The company operates in two primary business areas: product and service. In its product business, Advanced Media provides application licenses that utilize AmiVoice, while its service business delivers customized solutions for enterprise users and general consumers. The company's technology has applications across various sectors, including call centers, healthcare, logistics, mobile communication, conference proceedings, and language education. By focusing on human-computer interaction, Advanced Media aims to facilitate natural communication between people and machines, enhancing efficiency and user experience in diverse fields.
Gene Techno Science is engaged in the research and development of biopharmaceutical products and biosimilars in Japan. The company develops drugs for the treatment of immunological, cardiovascular, ophthalmic, infectious, and renal diseases as well as oncology drugs. It also offers Filgrastim for the treatment of cancer. Gene Techno Science was founded in 2001 and is headquartered in Sapporo, Japan.
SymBio Pharmaceuticals Limited is a biopharmaceutical company based in Tokyo, Japan, focused on the research, development, manufacturing, and marketing of pharmaceutical drugs, primarily in the fields of oncology and hematology. The company develops various anti-cancer agents, including Treakisym, which is used to treat non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia, and is currently undergoing Phase III trials for relapsed/refractory diffuse large B-cell lymphoma. Additionally, SymBio is working on several other drug formulations, including SyB L-1701, SyB L-1702, and Rigosertib SyB-C-0501, as well as SyB L-1101 and SyB C-1101 for higher-risk myelodysplastic syndromes. The company also has a candidate, SyB V-1901, aimed at treating infectious diseases. SymBio Pharmaceuticals operates primarily in Japan, South Korea, China, Hong Kong, Taiwan, and Singapore.
NanoCarrier Co., Ltd. is a Japanese pharmaceutical company that specializes in the research, development, production, and sale of cancer treatment products utilizing micellar nanoparticle technology. Founded in 1996 and headquartered in Kashiwa, Japan, the company has developed a diverse product pipeline aimed at various types of cancer. Key products include NC-6004, a Cisplatin micelle targeting cancers such as pancreatic and lung cancer; VB-111, a non-replicating Adeno 5 vector for treating recurrent glioblastoma and ovarian cancer; and NC-6300, an Epirubicin micelle for soft tissue sarcoma. Additional candidates include NC-4016, a Dach-platinum micelle for solid tumors, and NK105, a Paclitaxel micelle aimed at breast and gastric cancers. NanoCarrier is focused on advancing its innovative technologies to improve treatment options for cancer patients.
SymBio Pharmaceuticals Limited is a biopharmaceutical company based in Tokyo, Japan, focused on the research, development, manufacturing, and marketing of pharmaceutical drugs, primarily in the fields of oncology and hematology. The company develops various anti-cancer agents, including Treakisym, which is used to treat non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia, and is currently undergoing Phase III trials for relapsed/refractory diffuse large B-cell lymphoma. Additionally, SymBio is working on several other drug formulations, including SyB L-1701, SyB L-1702, and Rigosertib SyB-C-0501, as well as SyB L-1101 and SyB C-1101 for higher-risk myelodysplastic syndromes. The company also has a candidate, SyB V-1901, aimed at treating infectious diseases. SymBio Pharmaceuticals operates primarily in Japan, South Korea, China, Hong Kong, Taiwan, and Singapore.